热门资讯> 正文
RedHill收到总计110万美元的Talicia许可付款
2025-08-18 21:20
- RedHill Biopharma (NASDAQ:RDHL) on Monday announced that it has received its first Talicia ex-U.S. sales milestone, royalties and other payments totaling approximately $1.1 million.
- Talicia is the first-line therapy prescribed by U.S. gastroenterologists for treatment of H. pylori infection.
- RDHL +19.85% premarket to $1.63.
- Source: Press Release
More on RedHill
- Financial information for RedHill
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。